Next Article in Journal
The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs–TKIs: A Retrospective Multicentric Study
Previous Article in Journal
Correction: Barthélémy et al. Direct Comparative Analysis of a Pharmacogenomics Panel with PacBio Hifi® Long-Read and Illumina Short-Read Sequencing. J. Pers. Med. 2023, 13, 1655
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 14
Issue 10
10.3390/jpm14101029
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Patients’ Satisfaction after the Treatment of Moderate Sleep Apnea and Nocturnal Bruxism with Botox or/and Thermoformed Occlusal Splints: A Pilot Study

by
Taalat Gabriel Rezk Gavrilă
1,2,
Anamaria Bechir
3,*,
Andrada Camelia Nicolau
4,* and
Edwin Sever Bechir
5
1
Doctoral School in Dental Medicine, “Titu Maiorescu” University of Bucharest, 189 Calea Vacaresti, 040056 Bucharest, Romania
2
Efface Aesthetic Clinic, The CIBA Building, 146 Hagley Road, Edgbaston, Birmingham B16 9NX, UK
3
Faculty of Dental Medicine, “Titu Maiorescu” University of Bucharest, 67A Gh. Petrascu Street, 031592 Bucharest, Romania
4
Faculty of Medicine, Transilvania University of Brasov, 56 Nicolae Balcescu Str., 500019 Brasov, Romania
5
Faculty of Dental Medicine, “George Emil Palade” University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 38 Gh. Marinescu Street, 540142 Targu Mures, Romania
*
Authors to whom correspondence should be addressed.
J. Pers. Med. 2024, 14(10), 1029; https://doi.org/10.3390/jpm14101029
Submission received: 27 August 2024 / Revised: 19 September 2024 / Accepted: 24 September 2024 / Published: 26 September 2024
(This article belongs to the Section Personalized Therapy and Drug Delivery)
Browse Figures
Versions Notes

Abstract

:
Background: Sleep apnea and nocturnal bruxism belong to sleep disorders that can affect the quality of life. The aim of this study was to investigate the effects on patients with moderate sleep apnea and nocturnal bruxism of Botox injection as monotherapy or associated with wearing thermoformed occlusal splints and to determine the patients’ satisfaction degree after the applied treatments. Methods: The selected patients for study were divided into two groups: in the first group, the patients (n = 18) treatment consisted of injecting Botox (Allergan) into the masseter muscle as monotherapy; in the second group, the patients (n = 18) benefited from associated therapy, Botox injections in masseter muscle, and the wear of thermoformed occlusal splints. At baseline, at three weeks, at three months, and six months after the effectuation of therapies, the monitoring sessions were realized. Results: The associated therapy presented better results in decreasing the studied symptoms than the monotherapy. Both therapies improved patient satisfaction. Conclusions: The applied therapies for treating the specific symptomatology in moderate sleep apnea and sleep bruxism were efficacious. Patient satisfaction was very good in both groups after the applied treatments, but the associated therapy presented better results than monotherapy.

1. Introduction

Sleep apnea and bruxism are sleep disorders with multifactorial etiologies, but stress is involved in their etiologies, alongside the presence of acute and chronic diseases [1].
Sleep apnea, characterized by breathing stopping when asleep, is associated with a decrease in oxygen saturation in sleep and disturbs the quality and duration of sleep, inducing the apparition of symptoms such as loud and disruptive snoring, gasping for air during sleep, and daytime fatigue [2].
The prevalence of sleep disorders has increased in recent decades. According to research realized by Lechner et al. [3], 38% of men and 30.4% of women reported snoring at night; also, 8.7% of men and 5.6% of women declared that they stopped breathing at night [4,5,6].
According to their severity, sleep apnea can be classified as mild, moderate, or severe [7,8].
The specific feature of sleep apnea is represented by recurrent pauses in respiration, which induce intermittent hypoxia, hypercapnia, and oxygen desaturation in the blood, which can suddenly increase the risk of various diseases [9].
Bruxism (teeth grinding) is a parafunctional oral activity. Teeth grinding or clenching during sleep is known as nocturnal bruxism [10,11].
Bruxism is an illness with complex pathology due to various primary or secondary factors (vicious habits such as smoking and/or alcohol/drug abuse, chronic fatigue, insomnia, occlusal imbalances, facial muscle or nerve dysfunctions, anxious states, stress, administration of antidepressants, epilepsy, etc.) [12].
The prevalence of sleep bruxism is between 22.17% and 24.89% of the European population [13]. It has been noticed that a significant factors in the apparition of sleep bruxism are age and gender (it is more frequent in women) [14].
Bruxism can be classified into nocturnal and diurnal/awake bruxism. Regarding severity, bruxism can be mild, moderate, or severe [15,16].
The characteristic symptomatology of moderate nocturnal bruxism manifests itself in the morning and is represented by facial pain, stiffness of the masticatory muscles and temporomandibular joint (TMJ), discomfort when mobilizing the temporomandibular joint, headache, and alteration of the structure of the dental hard tissues [17,18]. This condition can remain undiagnosed until the apparition of local dental lesions (repeated friction of the occlusal surface of the teeth that can induce enamel abrasion, enamel cracks, and carious lesions) and, ulteriorly, the apparition of affections in the orofacial area [19,20].
In establishing the correct diagnosis of moderate sleep apnea and moderate nocturnal bruxism, an important role belongs to the partners of the affected persons, who can observe the characteristic manifestations observed during sleep [21,22].
Sleep apnea and nocturnal bruxism negatively affect sleep quality and patient quality of life [23,24,25].
Botulinum toxin type A (BoNT-A), the purified form of the strongest poison known, is obtained from Clostridium botulinum type A. It is used for stopping the delivery of acetylcholine, and it is used for treating many diseases, like chronic sialorrhea, muscular dystonia, and spasm, but also in cosmetic applications [25,26,27,28,29].
Intraoral dental devices such as occlusal splints or thermoformed mouthpieces are recommended to decrease inappropriate occlusal forces due to nocturnal bruxism. At the same time, by increasing the space between the dental arches in occlusion, occlusal splints can be used to improve the symptoms characteristic of nocturnal apnea [30,31].
The aim of this study was to investigate the effects of Botox injection therapy, with or without wearing thermoformed occlusal splints, on patients with moderate sleep apnea and nocturnal bruxism and to determine the patients’ satisfaction degree after completing the applied treatments. The research hypothesis was that there is a correlation between the effectuated treatments (with Botox Allergan and/or occlusal splints) and the patients’ satisfaction at the end of the effectuated treatments.

2. Materials and Methods

This study was realized in conformity with the ethical principles and the good clinical practice of the Helsinki Declaration [32].
The procedures of this study were authorized by the Ethics Committee of the Faculty of Dental Medicine, Titu Maiorescu University in Bucharest (Decision No. 6 of 14 January 2019). This study was performed between March 2019 and April 2024, but the COVID-19 pandemic conditions caused a 14-month break in research.

2.1. Selection of Patients

The selected patients were properly and individually informed regarding the demands of this study, and they signed the informed consent.
All authors attended calibration courses to ensure the accuracy of each patient’s anamnesis, clinical examination, diagnosis, and then similar application of clinical procedures for the reliability of the results.
The presence of sleep apnea and nocturnal bruxism symptoms was assessed by anamnesis, oral examination, and the utilization of questionnaires for the objective and subjective symptoms and regarding the satisfaction and quality of life related to sleep bruxism and nocturnal bruxism (used at baseline and at the last monitoring session). The complaints that were taken into consideration at anamnesis of sleep apnea and nocturnal bruxism were morning headaches, facial pain or fatigue, jaw-muscle fatigue, teeth grinding or jaw clenching sounds during sleep (as observed by the family or the sleep partner), and self-perception of teeth grinding and/or jaw clenching.
The objective symptomatology of bruxism that was observed at intraoral examination was related to unphysiological tooth wear, hypertrophy or hypertonicity of the masticatory muscle bundles, trismus, tongue indentation, and buccal mucosa ridges.
The questionnaire for subjective symptoms to ascertain the patients with sleep apnea and nocturnal bruxism contained seven questions: awakening in the morning with a dry mouth or sore throat; morning pain in masseter muscles; morning fatigue; morning headaches and jaw pain; diurnal difficulty in focusing; excessive daytime sleepiness.
This questionnaire was completed by both the patients and their partners.
The selected patients (n = 36, 24 female and 12 male), with moderate sleep apnea and moderate nocturnal bruxism, were divided into two groups.
The first group of 18 patients (G1) was treated by injecting Botox (Allergan, AbbVie Ltd., Maidenhead, Berkshire, SL6 4UB, UK) into the masseter muscle.
The 18 patients in the second group (G2) benefited from associated therapy represented by injections with Botox and the wear of thermoformed occlusal splints applied to the mandibular dental arch.
The sample of patients participating in this study is presented in Table 1.
Inclusion criteria were the following: male and female patients between 31 and 50 years of age with good health status; moderate sleep apnea and nocturnal bruxism symptomatology; moderate tooth wear; non-smoker patients; absence of parafunctional habits; confirmed non-allergic patients for use of dental materials; the patient’s acceptance to participate in this study with signed informed consent; the possibility of patients to come for the effectuation of treatments and follow-up sessions.
Exclusion criteria were the following: Botox allergy; allergy to the materials used for thermoformed occlusal splints; more than two missing teeth in the posterior area of the dental arches; extended prosthetic restorations; adult orthodontic patients; upper respiratory and pulmonary disorders; heart disease; simulators; infections; systemic disorders/diseases; pregnancy; lactation; antipsychotic or/and psychotropic treatments; patients with mental disabilities; uncooperative patients.
The flow diagram of this study is presented in Figure 1.

2.2. Performing Botox-Allergan Injections

Prior to beginning the therapies, a Botox allergy test was performed on each patient.
Botox (Allergan) powder (vacuum-dried Clostridium botulinum type A toxin) was solubilized and diluted under sterile conditions (in conformity with the manufacturer’s instructions [33,34]) with 2.5 mL of bacteriostatic 0.9% sodium chlorine per 100 units of Botox powder. Aespio fine micro syringes and BD Microlance 3 needles were used for administration of the treatment with Botox (Figure 2). The points of injection were noted after careful palpation of the temporomandibular area. In addition, measurements were made to ensure the accurate localization of each muscle bundle. A skin marker was used to map the injection points to ensure precision and reduce the risk of asymmetry. All patients were asked to clench their jaws so the masseter muscle could be identified more easily. The angle and the edge of the mandible were drawn. After measuring the drawing lines of the sides of the masseter muscle, the final draw was at least 1 cm lower than the edge of the masseter. In general, the focus was on the lower part of the masseter muscle. A total of 5 units of Botox solution were injected at 5 points on the masseters, at a distance of 1 cm between them and 1 cm from the previously drawn edges, in order to limit the possibility of affecting other muscles. The masseter muscle is a very strong muscle and needs much larger amounts of Botox than other muscles of the face. An entire ampoule of 50 units was used for the first treatment. After 3 weeks from the first treatment, the patients were recalled to verify their progress. During monitoring, after obtaining the results, if it was necessary, another 50 units of Botox were injected, but these cases were exceptions. The next assessments were after three and six months. The Botox injection sites used in this study are presented in Figure 3.
Always, bilateral Botox injections were performed, even if one side of the masseter muscle was stronger or more developed than the other. At baseline, the same amount of Botox was injected on both sides. At the first follow-up (performed after three weeks), a different quantity of Botox was injected on one side compared to the other, as needed. After these three weeks, there was a pause in the injection of Botox in order to observe how the treatment of sleep apnea and nocturnal bruxism evolves. After the last monitoring session, Botox injections were administered as needed, between one and two injections per six months, according to the faster or slower metabolism of the patients.
In order to relieve the errors and realize good investigations, objective appreciations, measurements, and treatment, all the patient’s images were captured with the “ImageJ” and “OBSERV 520” systems and preserved on “Consentz® Pros” Clinic Management software system for the encrypted storage of patients’ data.

2.3. Manufacturing the Thermoformed Occlusal Splints

The thermoformed occlusal splints used in this study covered the mandibular dental arch in totality and were manufactured via the thermo- and vacuum processes. The hard layer of the Erkoloc-Pro sheet is made of polyethylene terephthalate glycol, and the soft layer is made of a thermoplastic polyurethane. The manufacturing was accomplished via vacuuming the softened Erkoloc-Pro sheet at approximately 130 °C on the model of hard plaster located in the Erkoform-3d+ thermoforming device (Erkodent-Erich Kopp GmbH, Pfalzgrafenweiler, Germany) [35]. After obtaining, via vacuum and pression, the specific shape of the thermoformed occlusal splints, they were processed, finished, and polished.
Thermoformed occlusal splints were distributed to the patients of the second group (G2) at baseline. These patients continued to wear the thermoformed occlusal splints even after the last assessment (six months).

2.4. Questionnaires Regarding the Symptomatology and the Satisfaction of Patients

Four assessments were performed (at baseline and then at three weeks, three months, and six months) to determine the presence of objective and subjective symptoms.
The objective symptoms were represented by the presence of signs of contraction in the temporal and masseter muscle bundles (hypertrophy or hypertonicity), trismus, tongue indentation, and buccal mucosa ridges.
To find out the existence of sleep apnea and nocturnal bruxism in the patients, a seven-question questionnaire was designed. These questions regarding subjective symptoms were necessary for the correct selection of patients in this study. Responses were presented in five grades: never (=strongly disagree), rarely (=disagree), sometimes (=not sure), usually (=agree), and always (=strongly agree), and were completed by the patients and by their bed partners (roommates). These questions were related to the following: awakening in the morning with a dry mouth or sore throat; morning pain in the masseter muscle; morning fatigue; morning headaches; jaw pains; diurnal (daytime) difficulty in focusing; excessive daytime sleepiness.
To reveal the satisfaction and quality of patients’ lives relating to the outcomes of applied treatments, a ten-question questionnaire was designed. Responses were presented in five grades: very dissatisfied, quite dissatisfied, neither satisfied nor dissatisfied, quite satisfied, and very satisfied. The used questions were the following: How satisfied are you now with your sleep? How satisfied are you now with your absence of contractions at bundle level in masseter muscle? How satisfied are you now with your ability to perform your daily living activities? How satisfied are you now with your capacity for work? How satisfied are you with your actual condition of concentration? How satisfied are you with the applied therapy? How satisfied are you now with your oral health? How satisfied are you now with yourself? How do you evaluate your quality of life now?

2.5. Statistical Analysis

The performed statistical study used the Fisher Exact Test program because the participant groups were reduced in number (G1 = 18 and G2 = 18). The Fisher Exact Test works as a possible substitute for Pearson’s chi-square test when sample sizes are small.
The Fisher Exact Test represents a good computational program for the small samples because it uses a calculator for a 2 × 2 contingency table. The test can evaluate the independence from two variables when the compared groups are not correlated.
In this pilot study, the results were studied regarding the degree of changes in patients’ life quality and in the patients’ bed partners at baseline and at the last follow-up after the treatments.
In Figure 4, the visit schedule of patients in this pilot study is depicted.

3. Results

During the monitoring period, at all four assessment sessions, it was noticed that all the investigated symptomatology decreased in intensity in both groups of patients (G1 and G2), which exhibited relief of discomfort in sleep apnea and nocturnal bruxism in comparison with baseline.
It was remarked that the therapy with Botox injections produced immediate and adequate results. It was observed that the provided results in the second group of patients (G2, which benefited from Botox-Allergan injections and wore thermoformed occlusal splints) were higher than in the first group of patients (G1, which benefited only from Botox-Allergan injections). In Figure 5, the aspect of a female patient belonging to the G2 group is presented, at baseline (left) and at the fourth assessment (right).
Table 2 presents the results regarding the studied objective symptoms, noted at baseline and at the last follow-up session.
It can be observed that initially the investigated objective symptomatology was present in all patients from both research groups (G1 and G2), and at the last evaluation session (performed at six months), no patient presented any of those objective symptoms.
The answers received from the patients and their bed partners to the questionnaire used for the subjective symptomatology of sleep apnea and nocturnal bruxism and filled out at baseline are presented in Table 3 (where never = strongly disagree; rarely = disagree; sometimes = not sure; usually = agree; always = strongly agree).
Table 4 presents the answers received at the last assessment from the patients and their bed partners to the questionnaire about the subjective symptoms of sleep apnea and nocturnal bruxism.
We mention the fact that “never” = “strongly disagree”, “rarely” = “disagree”, “sometimes” = “not sure”, “usually” = “agree”, and “always” = “strongly agree”.
It can be observed that the subjective symptomatology investigated at baseline was present in all patients from both research groups and in all patients’ bed partners. It is visible that the higher frequency was exhibited for answers with “sometimes” (not sure), “usually” (agree), and “always” (strongly agree) grades. At the last assessment (at six months), all the patients of the two investigated groups and all their bed partners had the highest frequency of subjective symptomatology noted with “never”, and the qualifiers “usually” (agree) and “always” (strongly agree) had the value 0 (=0%). The first group of patients did not wear thermoformed occlusal splints.
It should be mentioned that, at the second and third evaluation sessions (performed at three weeks and three months), all the noted values were situated between those of Table 2 and Table 4. These values were decreasing from “always” (=strongly agree) to “rarely” (disagree) and “never” (=strongly disagree) at the second and third evaluation sessions.
By studying the percentages of Table 2, Table 3 and Table 4, it can also be observed that the quality and well-being level of the life of patients were greatly improved in both groups at the end of the monitoring period compared with baseline assessment.
Table 5 presents the results regarding the changes in patients’ life quality at baseline and at the last follow-up session after applying the therapies.
The associated treatment with Botox injection and occlusal splints presented immediate results with good effects, and the patients declared that they were very satisfied with the obtained results. After the finalization of applied treatments, the filled-out questionnaires regarding the satisfaction of patients revealed that their life quality had greatly improved.
Table 6 presents the satisfaction degree in patients’ life quality after the applied treatments, noted in both groups of patients (G1: n = 18, only injected with Botox-Allergan, and G2: n = 18, who were injected with Botox and wore thermoformed occlusal splints) at baseline (before treatment) and at the fourth (last) follow-up session (after treatment).
By studying the p-values in Table 6 (realized with the Fisher Exact Test program), which compares the answers to the questions from the satisfaction questionnaire completed at baseline and at the end of the monitoring period, we can conclude the following:
  • The surveyed patients presented the highest statistical p values for “sleep disruption” (p = 5.00), followed by “nocturnal bruxism”, “dry mouth/sore throat”, “masseter pain”, and “difficulty in focusing” with equal values (p < 2.00), “excessive sleepiness” with the value p = 2.00, and “fatigue, headaches, and jaw pain” having the lowest value p = 1.21;
  • The surveyed patient bed partners presented the highest statistical p value for “waking, gasping, choking” with p = 5.00, followed by “mood changes” with a value of p = 3.32, “difficulty in focusing” with a value of p = 3.00, “nocturnal bruxism” with a value of p = 3.00, “sleep disruption” with p < 2.00, “excessive sleepiness” with the value of p = 1.29, and “snoring” with the lowest value of p = 1.00.
These statistical results reveal that both moderate sleep apnea and moderate sleep bruxism therapies have proven effective, and this has increased the satisfaction of all patients and their bed partners.

4. Discussion

Sleep apnea and bruxism are sleep disorders. These conditions can represent risk factors associated with specific clinical manifestations that affect the quality of life; therefore, it is very important that these disorders are treated [36]. Among the causes that can induce sleep disorders are depression, anxiety, constant stress, changing the time zone, various diseases (heart, stomach, kidney, or lung diseases), taking drugs that cause insomnia or drowsiness, environmental changes, aging, etc. [37].
Bruxism is an illness with complex pathology due to various primary or secondary factors (vicious habits such as smoking and/or alcohol/drug abuse, chronic fatigue, insomnia, occlusal imbalances, facial muscle or nerve dysfunctions, anxious states, stress, administration of antidepressants, epilepsy, etc.) [38,39].
The results of this study regarding therapy with Botox and occlusal splints for moderate sleep apnea and moderate sleep bruxism show that these types of treatments are non-invasive, reliable, facile to accomplish, reversible, beneficial, comfortable, and effortlessly accepted by patients.
Lobbezoo et al. [40] reported that sleep (nocturnal) bruxism is a masticatory muscle activity that occurs in sleep, and it can be distinguished as rhythmic or non-rhythmic. In healthy people, bruxism should not be considered a disorder but a behavior that may present a risk or protective factor in some particular clinical cases.
Shivamurthy et al. [41] consider that one of the predisposing factors for the development of temporomandibular disorders (which include bruxism) could be represented by stress, so screening performed at a young age could aid in the prevention and progression of the disease.
In accordance with many studies, botulinum toxin type A has proven its effectiveness in various therapies, but only when applied accurately [42,43,44,45,46].
In conformity with the review conducted by Li et al. [47], the therapy with Botox represents a reliable and efficient therapy in decreasing the pain intensity and ameliorating the functional movements of the masticatory muscles and temporomandibular joints in patients with temporomandibular dysfunctions. They consider that the dose of 60–100 U injected bilaterally can represent a beneficial solution for treating the pain that appeared due to temporomandibular dysfunctions. The rigidity of the masticatory muscles is decreased by injections with Botox, and the stiffness of the temporalis muscles is improved.
Due to the modification of masseter muscle function, changes appear in the other masticatory muscles too, which are favorable in offering functional and cosmetic outcomes. All this is achieved by the simultaneous evaluation and treatment of all the masticatory muscles, including the temporalis muscle [48].
According to Yağci et al. [49], the risk of bruxism is higher in depressed patients, those with poor quality of sleep, and those with shocking childish experiences.
The masseter muscle, although it is the strongest muscle in the human body, does not need to be weakened too much by injecting Botox, because it can lead to difficulties in the patient’s mastication, which negatively affects their functionality and quality of life [50,51]. Fortunately, any Botox treatment is completely reversible, and the muscles return to normal after a period of several months [52,53].
The beneficial mechanisms offered by the occlusal splints are not yet obvious [54], but the study conducted by Bergmann et al. [55] confirms the efficiency and safety of the use of occlusal splints in the treatment of sleep bruxism.
In their study, Albagieh et al. [56] concluded that occlusal splints can be used for the treatment of extensive variants of temporomandibular disorders (TMDs), as well as bruxism, headaches, reduced vertical dimension of occlusion, and so on, but there is no evident proof that treatment with occlusal splints is better than physiotherapy in the treatment of TMDs.
After the review realized by Duarte et al. [57], at the moment, there is not adequate scientific evidence to advocate or confirm the existence of a link between sleep, bruxism, and quality of life in the general population.
In their study, Mercan Başpınar et al. [25] observed that decreased oral health in relation to the quality of life and low sleep quality would be expected in the presence of nocturnal bruxism. They underlined the fact that the patients may not be aware of their situation until it is clearly presented by a dentist.
Because the etiology of sleep apnea and sleep bruxism is multifactorial, interdisciplinary collaboration is necessary to increase the success rate of treatment, and the ideal treatment options are represented by the multidisciplinary approaches [58,59].
The systematic review effectuated by Ferrillo [60] indicates that a multidisciplinary approach involving rehabilitation dentistry and physical medicine as well as psychology is compulsory for the suitable diagnosis and treatment of patients with sleep disorders.
Regarding the effectuated statistical data, initially, the simple Chi-test program was applied, but, unfortunately, the results were not relevant at all, and the values obtained were noted as “erroneous”. For this reason, the performed statistical study was with the Fisher Exact Test program. The p values obtained after applying this program confirmed the fact that the results of this study were relevant.
Despite the small sample sizes, this pilot study can contribute to the progress of clinical knowledge, and also, through the clinical and statistical significance, it has the possibility to contribute to the further development of clinical practice guidelines.
The clinical relevance of this pilot study is given by the favorable results obtained in the therapy with Botox with or without thermoformed occlusal splints, for moderate sleep apnea and moderate sleep bruxism. The limitations of this pilot study are due to the limited number of patients in the study groups and the relatively short time interval of the monitoring.

5. Conclusions

Associated therapy with Botox with or without thermoformed occlusal splints of moderate sleep apnea and moderate sleep bruxism represented a reliable and efficacious treatment for decreasing the specific symptomatology of these afflictions.
Also, the results of this study demonstrated that the applied therapies improved patient satisfaction and their quality of life.
Sleep apnea and sleep bruxism have significant implications for the health status and life satisfaction of those affected, so these conditions require a personalized approach to both diagnosis and management. Future studies with a larger number of patients with moderate sleep apnea and bruxism are needed.
In addition, the study of the cumulative action of factors such as gender, ages, smoking, consumption of alcohol, caffeine, drugs, and addictive substances can complete the interpretation of studies and of working hypotheses.

Author Contributions

Conceptualization, A.B. and E.S.B.; Data curation, A.C.N. and E.S.B.; Formal analysis, A.B. and E.S.B.; Investigation, T.G.R.G., A.B., A.C.N., and E.S.B.; Methodology, T.G.R.G. and A.C.N.; Project administration, E.S.B.; Resources, A.B. and E.S.B.; Software, T.G.R.G. and E.S.B.; Supervision, T.G.R.G. and A.B.; Validation, T.G.R.G., A.B. and A.C.N.; Visualization, A.B. and A.C.N.; Writing—original draft, T.G.R.G. and A.B.; Writing—review and editing, T.G.R.G., A.C.N. and E.S.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was realized in conformity with the ethical principles and the good clinical practice of the Helsinki Declaration [32]. The procedures of this study were authorized by the Ethics Committee of the Faculty of Dental Medicine, Titu Maiorescu University in Bucharest (Decision No. 6 of 14 January 2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study, and written informed consent has been obtained from the patients to publishing this paper.

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Cumpston, E.; Chen, P. Sleep Apnea Syndrome. [Updated 2023 Sep 4]. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, January 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK564431/ (accessed on 16 February 2024).
  2. Slowik, J.M.; Sankari, A.; Collen, J.F. Obstructive Sleep Apnea. [Updated 2024 Mar 21]. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, January 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK459252/ (accessed on 22 February 2024).
  3. Lechner, M.; Breeze, C.E.; Ohayon, M.M.; Kotecha, B. Snoring and breathing pauses during sleep: Interview survey of a United Kingdom population sample reveals a significant increase in the rates of sleep apnoea and obesity over the last 20 years—Data from the UK sleep survey. Sleep. Med. 2019, 54, 250–256. [Google Scholar] [CrossRef] [PubMed]
  4. Borsini, E.; Noguiera, F.; Nigro, C. Apnea-hypopnea index in sleep studies and the risk of over-simplification. Sleep Sci. 2018, 11, 45–48. [Google Scholar] [CrossRef] [PubMed]
  5. Abbasi, A.; Gupta, S.S.; Sabharwal, N.; Meghrajani, V.; Sharma, S.; Kamholz, S.; Kupfer, Y. A comprehensive review of obstructive sleep apnea. Sleep. Sci. 2021, 14, 142–154. [Google Scholar] [CrossRef] [PubMed]
  6. Leigh, C.; Faigenblum, M.; Fine, P.; Blizard, R.; Leung, A. General dental practitioners’ knowledge and opinions of snoring and sleep-related breathing disorders. Br. Dent. J. 2021, 1, 569–574. [Google Scholar] [CrossRef] [PubMed]
  7. Ayalew, M.P.; Nemomssa, H.D.; Simegn, G.L. Sleep apnea syndrome detection and classification of severity level from ECG and SpO2 signals. Health Technol. 2021, 5, 13. [Google Scholar] [CrossRef]
  8. Kazubowska-Machnowska, K.; Jodkowskam, A.; Michalek-Zrabkowska, M.; Wieckiewicz, M.; Poreba, R.; Dominiak, M.; Gac, P.; Mazur, G.; Kanclerska, J.; Martynowicz, H. The Effect of Severity of Obstructive Sleep Apnea on Sleep Bruxism in Respiratory Polygraphy Study. Brain Sci. 2022, 12, 828. [Google Scholar] [CrossRef]
  9. Lv, R.; Liu, X.; Zhang, Y.; Dong, N.; Wang, X.; He, Y.; Yue, H.; Yin, Q. Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome. Sig. Transduct. Target. Ther. 2023, 8, 218. [Google Scholar] [CrossRef]
  10. Bruxism: Teeth Grinding at Night. Available online: https://www.sleepfoundation.org/bruxism (accessed on 29 March 2024).
  11. Craciun, A.E.; Cerghizan, D.; Popsor, S.; Bica, C. Bruxism in Children and Adolescents and its Association with Some Possible Aetiological Factors. Curr. Health Sci. J. 2023, 49, 257–262. [Google Scholar] [CrossRef]
  12. Golanska, P.; Saczuk, K.; Domarecka, M.; Kuć, J.; Lukomska-Szymanska, M. Temporomandibular Myofascial Pain Syndrome—Aetiology and Biopsychosocial Modulation. A Narrative Review. Int. J. Environ. Res. Public Health 2021, 18, 7807. [Google Scholar] [CrossRef]
  13. Osses-Anguita, Á.E.; Sánchez-Sánchez, T.; Soto-Goñi, X.A.; García-González, M.; Alén Fariñas, F.; Cid-Verdejo, R.; Sánchez Romero, E.A.; Jiménez-Ortega, L. Awake and Sleep Bruxism Prevalence and Their Associated Psychological Factors in First-Year University Students: A Pre-Mid-Post COVID-19 Pandemic Comparison. Int. J. Environ. Res. Public Health 2023, 20, 2452. [Google Scholar] [CrossRef]
  14. Zieliński, G.; Pająk, A.; Wójcicki, M. Global Prevalence of Sleep Bruxism and Awake Bruxism in Pediatric and Adult Populations: A Systematic Review and Meta-Analysis. J. Clin. Med. 2024, 13, 4259. [Google Scholar] [CrossRef] [PubMed]
  15. Balasubramaniam, R.; Paesani, D.; Koyano, K.; Tsukiyama, Y.; Carra, M.C.; Lavigne, G.J. Sleep Bruxism. In Contemporary Oral Medicine; Farah, C., Balasubramaniam, R., McCullough, M., Eds.; Springer: Cham, Switzerland, 2019. [Google Scholar] [CrossRef]
  16. Available online: https://www.bruxism.org.uk/what-is-bruxism.php (accessed on 12 January 2024).
  17. Ohlmann, B.; Waldecker, M.; Leckelm, M.; Bömicke, W.; Behnisch, R.; Rammelsberg, P.; Schmitter, M. Correlations between Sleep Bruxism and Temporomandibular Disorders. J. Clin. Med. 2020, 9, 611. [Google Scholar] [CrossRef] [PubMed]
  18. Iacob, S.M.; Chisnoiu, A.M.; Objelean, A.; Fluerașu, M.I.; Moga, R.R.; Buduru, S.D. Correlation between bruxism, occlusal dysfunction and musculo-articular status. Rom. J. Oral Rehabil. 2022, 14, 48–55. [Google Scholar]
  19. Wetselaar, P.; Vermaire, E.J.H.; Lobbezoo, F.; Schuller, A.A. The prevalence of awake bruxism and sleep bruxism in the Dutch adult population. J. Oral Rehabil. 2019, 46, 617–623. [Google Scholar] [CrossRef] [PubMed]
  20. Thayer, M.L.T.; Ali, R. The dental demolition derby: Bruxism and its impact—Part 1: Background. Br. Dent. J. 2022, 232, 515–521. [Google Scholar] [CrossRef] [PubMed]
  21. Thomas, D.C.; Patel, J.; Kumar, S.S.; Dakshinamoorthy, J.; Greenstein, Y.; Kamalam Ravindran, H.; Kodaganallur Pitchumani, P. Sleep related bruxism—Comprehensive review of the literature based on a rare case presentation. Front. Oral Maxillofac. Med. 2024, 6, 1–14. Available online: https://fomm.amegroups.org/article/view/67995 (accessed on 12 March 2024). [CrossRef]
  22. The Link Between Sleep Apnea and Teeth Grinding. Available online: https://www.sleepfoundation.org/sleep-apnea/link-between-sleep-apnea-and-teeth-grinding (accessed on 8 December 2023).
  23. Özsoy, H.E.; Gaş, S.; Aydın, K.C. The Relationship between Stress Levels, Sleep Quality, and Oral Health-related Quality of Life in Turkish University Students with Self-reported Bruxism. J. Turk. Sleep Med. 2022, 9, 64–72. [Google Scholar] [CrossRef]
  24. Colonna, A.; Manfredini, D. Bruxism: An orthodontist’s perspective. Semin. Orthod. 2024, 30, 318–324. [Google Scholar] [CrossRef]
  25. Mercan Başpınar, M.; Mercan, Ç.; Mercan, M.; Arslan Aras, M. Comparison of the Oral Health-Related Quality of Life, Sleep Quality, and Oral Health Literacy in Sleep and Awake Bruxism: Results from Family Medicine Practice. Int. J. Clin. Pract. 2023, 30, 1186278. [Google Scholar] [CrossRef]
  26. Botulinum Toxin Type A, DRUGBANK Online. Available online: https://go.drugbank.com/drugs/DB00083 (accessed on 14 December 2023).
  27. Rasetti-Escargueil, C.; Palea, S. Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications. Toxins 2024, 16, 261. [Google Scholar] [CrossRef]
  28. Park, M.Y.; Ahn, K.Y. Scientific review of the aesthetic uses of botulinum toxin type A. Arch. Craniofac. Surg. 2021, 22, 1–10. [Google Scholar] [CrossRef] [PubMed]
  29. Brin, M.F.; Burstein, R. Botox (onabotulinumtoxinA) mechanism of action. Medicine 2023, 102 (Suppl. S1), e32372. [Google Scholar] [CrossRef] [PubMed]
  30. Bechir, E.S.; Bechir, A.; Arghir, O.A.; Ciavoi, G.; Gioga, C.; Curt Mola, F.; Dascalu, I.T. Results in the Use of Two Types of Polymeric Appliances in the Therapy of Some Mild Sleep Apnea Simptoms. Rev. Mat. Plast. Bucur. 2017, 54, 304–308. Available online: http://www.revmaterialeplastice.ro/archive.asp (accessed on 18 September 2021). [CrossRef]
  31. Costăchel, B.C.; Bechir, A.; Burcea, A.; Mihai, L.L.; Ionescu, T.; Marcu, O.A.; Bechir, E.S. Evaluation of Abfraction Lesions Restored with Three Dental Materials: A Comparative Study. Clin. Pract. 2023, 13, 1043–1058. [Google Scholar] [CrossRef] [PubMed]
  32. Peters, B. Patient Rights: What Is the Declaration of Helsinki? Available online: https://www.verywellhealth.com/declaration-of-helsinki-4846525 (accessed on 28 February 2022).
  33. BOTOX 100 Allergan Units Powder, emc (Electronic Medicines Compendium). Available online: https://www.medicines.org.uk/emc/product/859/smpc#gref (accessed on 28 July 2024).
  34. PrBOTOX® onabotulinumtoxinA for Injection Ph. Eur Allergan Inc. Markham, ON L6G 0B5. Available online: https://pdf.hres.ca/dpd_pm/00060199.PDF (accessed on 8 August 2024).
  35. Erkoloc-Pro Dual Laminates, National Dental Supplies Ltd. Available online: https://ndsonline.co.uk/products/proform-3mm-dual-laminate-blanks-erkodent (accessed on 12 May 2022).
  36. González, A.; Montero, J.; Gómez Polo, C. Sleep Apnea-Hypopnea Syndrome and Sleep Bruxism: A Systematic Review. J. Clin. Med. 2023, 23, 910. [Google Scholar] [CrossRef]
  37. Merrill, R.M.; Ashton, M.K.; Angell, E. Sleep disorders related to index and comorbid mental disorders and psychotropic drugs. Ann. Gen. Psychiatry 2023, 22, 23. [Google Scholar] [CrossRef]
  38. Cervantes-Chavarría, A.R.; Utsman-Abarca, R.; Herrero-Babiloni, A. Bruxism an issue between the myths and fact. Odovtos Int. J. Dent. Sci. 2022, 24, 15–21. [Google Scholar] [CrossRef]
  39. Vlăduțu, D.E.; Ionescu, M.; Mercuț, R.; Noveri, L.; Lăzărescu, G.; Popescu, S.M.; Scrieciu, M.; Manolea, H.O.; Iacov Crăițoiu, M.M.; Ionescu, A.G.; et al. Ecological Momentary Assessment of Masseter Muscle Activity in Patients with Bruxism. Int. J. Environ. Res. Public Health 2023, 20, 581. [Google Scholar] [CrossRef]
  40. Lobbezoo, F.; Ahlberg, J.; Raphael, K.G.; Wetselaar, P.; Glaros, A.G.; Kato, T.; Santiago, V.; Winocur, E.; De Laat, A.; De Leeuw, R.; et al. International consensus on the assessment of bruxism: Report of a work in progress. J. Oral Rehabil. 2018, 45, 837–844. [Google Scholar] [CrossRef]
  41. Shivamurthy, P.G.; Kumari, N.; Sadaf, A.; Meghana, M.B.; Azhar, H.; Sabrish, S. Use of Fonseca’s Questionnaire to assess the prevalence and severity of Temporomandibular disorders among university students—A cross sectional study. Dentistry 3000 2022, 10, a001. [Google Scholar] [CrossRef]
  42. Witmanowski, H.; Błochowiak, K. The whole truth about botulinum toxin—A review. Postep. Dermatol. Alergol. 2020, 37, 853–861. [Google Scholar] [CrossRef] [PubMed]
  43. Dickison, C.; Leggit, J.C. Botulinum toxin for chronic pain: What’s on the horizon? J. Fam. Pract. 2021, 70, 442–449. [Google Scholar] [CrossRef] [PubMed]
  44. Abbas, R.H.; Koshy, R.R.; Fathima, Y.; Weerasekara, R.A.; Sherin, Z.; Selvakumar, N.; Korrapati, N.H. The clinical approach to botulinum toxin in dermatology: A literature review. CosmoDerma 2023, 3, 1–8. [Google Scholar] [CrossRef]
  45. Malcangi, G.; Patano, A.; Pezzolla, C.; Riccaldo, L.; Mancini, A.; Di Pede, C.; Inchingolo, A.D.; Inchingolo, F.; Bordea, I.R.; Dipalma, G.; et al. Bruxism and Botulinum Injection: Challenges and Insights. J. Clin. Med. 2023, 12, 4586. [Google Scholar] [CrossRef]
  46. Ângelo, D.F.; Sanz, D.; Maffia, F.; Cardoso, H.J. Outcomes of IncobotulinumtoxinA Injection on Myalgia and Arthralgia in Patients Undergoing Temporomandibular Joint Arthroscopy: A Randomized Controlled Trial. Toxins 2023, 15, 376. [Google Scholar] [CrossRef]
  47. Li, K.; Tan, K.; Yacovelli, A.; Bi, W.G. Effect of botulinum toxin type A on muscular temporomandibular disorder: A systematic review and meta-analysis of randomized controlled trials. J. Oral Rehabil. 2024, 51, 886–897. [Google Scholar] [CrossRef]
  48. Mierzwa, D.; Olchowy, C.; Olchowy, A.; Nawrot-Hadzik, I.; Dąbrowski, P.; Chobotow, S.; Grzech-Leśniak, K.; Kubasiewicz-Ross, P.; Dominiak, M. Botox Therapy for Hypertrophy of the Masseter Muscle Causes a Compensatory Increase of Stiffness of Other Muscles of Masticatory Apparatus. Life 2022, 12, 840. [Google Scholar] [CrossRef]
  49. Yağci, İ.; Taşdelen, Y.; Kivrak, Y. Childhood Trauma, Quality of Life, Sleep Quality, Anxiety and Depression Levels in People with Bruxism. Noro. Psikiyatr. Ars. 2020, 57, 131–135. [Google Scholar] [CrossRef]
  50. Chirico, F.; Bove, P.; Fragola, R.; Cosenza, A.; De Falco, N.; Lo Giudice, G.; Audino, G.; Rauso, G.M. Biphasic Injection for Masseter Muscle Reduction with Botulinum Toxin. Appl. Sci. 2021, 11, 6478. [Google Scholar] [CrossRef]
  51. Corcoran, N.M.; Goldman, E.M. Anatomy, Head and Neck, Masseter Muscle. [Updated 2023 Jun 5]. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, January 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK539869/ (accessed on 21 April 2024).
  52. Rathod, N.N.; John, R.S. Botulinum Toxin Injection for Masseteric Hypertrophy Using 6 Point Injection Technique—A Case Report. Proposal of a Clinical Technique to Quantify Prognosis. Clin. Cosmet. Investig. Dent. 2023, 15, 45–49. [Google Scholar] [CrossRef]
  53. Blanco-Rueda, J.A.; López-Valverde, A.; Márquez-Vera, A.; Méndez-Sánchez, R.; López-García, E.; López-Valverde, N. Preliminary Findings of the Efficacy of Botulinum Toxin in Temporomandibular Disorders: Uncontrolled Pilot Study. Life 2023, 13, 345. [Google Scholar] [CrossRef] [PubMed]
  54. Jagger, R.; King, E. Occlusal Splints for Bruxing and TMD—A Balanced Approach? Restorative Dentistry. Dent. Update 2018, 45, 912–918. [Google Scholar] [CrossRef]
  55. Bergmann, A.; Edelhoff, D.; Schubert, O.; Erdelt, K.J.; Pho Duc, J.M. Effect of treatment with a full-occlusion biofeedback splint on sleep bruxism and TMD pain: A randomized controlled clinical trial. Clin. Oral Investig. 2020, 24, 4005–4018. [Google Scholar] [CrossRef] [PubMed]
  56. Albagieh, H.; Alomran, I.; Binakresh, A.; Alhatarisha, N.; Almeteb, M.; Khalaf, Y.; Alqublan, A.; Alqahatany, M. Occlusal splints-types and effectiveness in temporomandibular disorder management. Saudi Dent. J. 2023, 35, 70–79. [Google Scholar] [CrossRef]
  57. Duarte, J.; Pauletto, P.; Massignan, C.; Bolan, M.; Domingos, F.L.; Curi Hallal, A.L.; De Luca Canto, G. Association between Sleep Bruxism and Quality of Life: A Systematic Review. J. Oral Facial Pain Headache 2020. 34, 341–352. [CrossRef]
  58. Walentek, N.P.; Schäfer, R.; Bergmann, N.; Franken, M.; Ommerborn, M.A. Relationship between Sleep Bruxism Determined by Non-Instrumental and Instrumental Approaches and Psychometric Variables. Int. J. Environ. Res. Public Health 2024, 21, 543. [Google Scholar] [CrossRef]
  59. Lal, S.J.; Sankari, A.; Weber, K.K. Bruxism Management. [Updated 2024 May 1]. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, January 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK482466/ (accessed on 22 April 2024).
  60. Ferrillo, M.; Ammendolia, A.; Paduano, S.; Calafiore, D.; Marotta, N.; Migliario, M.; Fortunato, L.; Giudice, A.; Michelotti, A.; de Sire, A. Efficacy of rehabilitation on reducing pain in muscle-related temporomandibular disorders: A systematic review and meta-analysis of randomized controlled trials. J. Back Musculoskelet. Rehabil. 2022, 35, 921–936. [Google Scholar] [CrossRef]
Jpm 14 01029 g001
Figure 1. The flow chart of this study.
Figure 1. The flow chart of this study.
Jpm 14 01029 g001
Jpm 14 01029 g002
Figure 2. Presentation of (a) Botox powder; (b) Sodium chlorine solution; (c) Aespio fine micro syringe; (d) BD Microlance needles.
Figure 2. Presentation of (a) Botox powder; (b) Sodium chlorine solution; (c) Aespio fine micro syringe; (d) BD Microlance needles.
Jpm 14 01029 g002
Jpm 14 01029 g003
Figure 3. The Botox injection sites used in this study.
Figure 3. The Botox injection sites used in this study.
Jpm 14 01029 g003
Jpm 14 01029 g004
Figure 4. Visit schedule.
Figure 4. Visit schedule.
Jpm 14 01029 g004
Jpm 14 01029 g005
Figure 5. Aspect of a female patient belonging to the G2 group, at baseline (left) and at the fourth assessment (right), after the injection with Botox and wearing of thermoformed occlusal splint.
Figure 5. Aspect of a female patient belonging to the G2 group, at baseline (left) and at the fourth assessment (right), after the injection with Botox and wearing of thermoformed occlusal splint.
Jpm 14 01029 g005
Table 1. Sample of the patients participating in this study.
Table 1. Sample of the patients participating in this study.
All PatientsGroup 1 (G1)Group 2 (G2)
No of patients361818
Age (mean ± years)31–50 yearMale33–50 (mean 41.5 ± 8.5)
Female31–48 (mean 39.5 ± 8.5)
Gender M/FMale 12 (34%)6 (33.33%)6 (33.33%)
Female 24 (66%)12 (66.66%)12 (66.66%)
Table 2. The results regarding the studied objective symptoms, noted at baseline and at the last follow-up session.
Table 2. The results regarding the studied objective symptoms, noted at baseline and at the last follow-up session.
Objective SymptomPatients GroupBaselineLast Follow-Up Session
PresentAbsentPresentAbsent
1.Contraction of the temporal muscle bundlesG118 (100%)0 (0%)0 (0%)18 (100%)
G218 (100%)0 (0%)0 (0%)18 (100%)
2.Contraction of the masseter muscle bundlesG118 (100%)0 (0%)0 (0%)18 (100%)
G218 (100%)0 (0%)0 (0%)18 (100%)
3.TrismusG118 (100%)0 (0%)0 (0%)18 (100%)
G218 (100%)0 (0%)0 (0%)18 (100%)
4.Tongue indentationG118 (100%)0 (0%)0 (0%)18 (100%)
G218 (100%)0 (0%)0 (0%)18 (100%)
5.Buccal mucosa ridgesG118 (100%)0 (0%)0 (0%)18 (100%)
G218 (100%)0 (0%)0 (0%)18 (100%)
Table 3. Questionnaire for the patients and their bed partners about subjective symptoms: responses at baseline.
Table 3. Questionnaire for the patients and their bed partners about subjective symptoms: responses at baseline.
Questions Addressed to Patients (n = 36)ResponsesQuestions Addressed to Patients’ Bed Partners (n = 36)Responses
Sleep disruption
(episodes of stopping breathing)		never3 (=8.33%)Sleep disruption
(episodes of stopping breathing)		never0 (=0%)
rarely 11 (=30.55%)rarely 1 (=2.77%)
sometimes5 (=13.88%)sometimes2 (=5.55%)
usually11 (=30.55%)usually4 (=11.11%)
always6 (=16.66%)always29 (=80.55%)
Nocturnal bruxism (teeth grinding or clenching)never0 (=0%)Nocturnal bruxism
(teeth grinding or
clenching)		never1 (=2.77%)
rarely 1 (=2.77%)rarely 3 (=8.33%)
sometimes6 (=16.66%)sometimes6 (=16.66%)
usually9 (=25.0%)usually12 (=33.33%)
always20 (=55.55%)always14 (=38.88%)
Awakening in the morning with a dry mouth or sore throatnever0 (=0%)Snoringnever0 (=0%)
rarely 4 (=11.11%)rarely 2 (=5.55%)
sometimes7 (=19.44%)sometimes13 (=36.11%)
usually12 (=33.33%)usually12 (=33.33%)
always13 (=36.11%)always9 (=25.0%)
Morning pain in the masseter musclenever0 (=0%)Waking during the night and gasping or chokingnever0 (=0%)
rarely 3 (=8.33%)rarely 4 (=11.11%)
sometimes4 (=11.11%)sometimes5 (=13.88%)
usually9 (=25.0%)usually19 (=52.77%)
always20 (=55.55%)always8 (=22.22%)
Morning fatigue,
headaches, and jaw pain		never0 (=0%)Mood changes
(e.g., depressive or
irritable)		never3 (=8.33%)
rarely 5 (=13.88%)rarely 9 (=25.0%)
sometimes8 (=22.22%)sometimes8 (=22.22%)
usually12 (=33.33%)usually9 (=25.0%)
always11 (=30.55%)always7 (=19.44%)
Diurnal (daytime)
difficulty in focusing		never0 (=0%)Diurnal (daytime)
difficulty in focusing		never1 (=2.77%)
rarely 1 (=2.77%)rarely 3 (=8.33%)
sometimes12 (=33.33%)sometimes5 (=13.88%)
usually12 (=33.33%)usually16 (=44.44%)
always11 (=30.55%)always12 (=33.33%)
Excessive daytime sleepinessnever1 (=2.77%)Excessive daytime sleepinessnever6 (=16.66%)
rarely 8 (=22.22%)rarely 6 (=16.66%)
sometimes9 (=25.0%)sometimes7 (=19.44%)
usually7 (=19.44%)usually8 (=22.22%)
always11 (=30.55%)always9 (=25.0%)
Table 4. Questionnaire for the patients and their bed partners about subjective symptoms: responses at the last follow-up session.
Table 4. Questionnaire for the patients and their bed partners about subjective symptoms: responses at the last follow-up session.
Questions Addressed to Patients (n = 36)ResponsesQuestions Addressed to Patients’ Bed Partners (n = 36)Responses
Sleep disruption
(episodes of stopping breathing)		never30 (=83.33%)Sleep disruption
(episodes of stopping breathing)		never26 (=72.22%)
rarely 2 (=5.55%)rarely 6 (=16.66%)
sometimes3 (=8.33%)sometimes4 (=11.11%)
usually1 (=2.77%)usually0 (=0%)
always0 (=0%)always0 (=0%)
Nocturnal bruxism (teeth grinding or clenching)never31 (=86.11%)Nocturnal bruxism
(teeth grinding or
clenching)		never27 (=75%)
rarely 3 (=8.33%)rarely 6 (=16.66%)
sometimes1 (=2.77%)sometimes3 (=8.33%)
usually1 (=2.77%)usually0 (=0%)
always0 (=0%)always0 (=0%)
Awakening in the morning with a dry mouth or sore throatnever31 (=86.11%)Snoringnever30 (=83.33%)
rarely 4 (=11.11%)rarely 3 (=8.33%)
sometimes1 (=2.77%)sometimes2 (=5.55%)
usually0 (=0%)usually1 (=2.77%)
always0 (=0%)always0 (=0%)
Morning pain in the masseter musclenever32 (=88.88%)Waking during the night and gasping or chokingnever28 (=77.77%)
rarely 2 (=5.55%)rarely 5 (=13.88%)
sometimes2 (=5.55%)sometimes3 (=8.33%)
usually0 (=0%)usually0 (=0%)
always0 (=0%)always0 (=0%)
Morning fatigue,
headaches, and jaw pain		never29 (=80.55%)Mood changes
(e.g., depressive or
irritable)		never30 (=83.33%)
rarely 4 (=11.11%)rarely 3 (=8.33%)
sometimes3 (=8.33%)sometimes3 (=8.33%)
usually0 (=0%)usually0 (=0%)
always0 (=0%)always0 (=0%)
Diurnal (daytime)
difficulty in focusing		never26 (=72.22%)Diurnal (daytime)
difficulty in focusing		never27 (=75%)
rarely 7 (=19.44%)rarely 7 (=19.44%)
sometimes3 (=8.33%)sometimes2 (=5.55%)
usually0 (=0%)usually0 (=0%)
always0 (=0%)always0 (=0%)
Excessive daytime sleepinessnever28 (=77.77%)Excessive daytime sleepinessnever29 (=80.55%)
rarely 4 (=11.11%)rarely 4 (=11.11%)
sometimes4 (=11.11%)sometimes3 (=8.33%)
usually0 (=0%)usually0 (=0%)
always0 (=0%)always0 (=0%)
Table 5. Results regarding the degree of changes in patients’ life quality after the applied treatments (baseline and last follow-up).
Table 5. Results regarding the degree of changes in patients’ life quality after the applied treatments (baseline and last follow-up).
GroupVery DissatisfiedQuite DissatisfiedNeither Satisfied Nor DissatisfiedQuite SatisfiedVery Satisfied
BLFuBLFuBLFuBLFuBLFu
How satisfied are you with your sleep?G112
66.66%		0
0%		2
11.11%		0
0%		2
11.11%		0
0%		1
5.55%		2
11.11%		1
5.55%		16
88.88%
G211
61.11%		0
0%		3
16.66%		0
0%		2
11.11%		0
0%		1
5.55%		1
5.55%		1
5.55%		17
94.44%
How satisfied are you about the contractions in masseter muscle?G110
55.55%		0
0%		4
22.22%		0
0%		2
11.11%		1
5.55%		1
5.55%		2
11.11%		1
5.55%		15
83.33%
G212
66.66%		0
0%		3
16.66%		0
0%		2
11.11%		0
0%		1
5.55%		1
5.55%		0
0%		17
94.44%
How satisfied are you now about your ability to perform daily living activities?G111
61.11%		0
0%		5
27.77%		0
0%		1
5.55%		0
0%		1
5.55%		2
11.11%		0
0%		16
88.88%
G212
66.66%		0
0%		4
22.22%		0
0%		1
5.55%		0
0%		1
5.55%		1
5.55%		0
0%		17
94.44%
How satisfied are you now with your capacity for work?G110
55.55%		0
0%		5
27.77%		0
0%		2
11.11%		0
0%		1
5.55%		2
11.11%		0
0%		16
88.88%
G210
55.55%		0
0%		4
22.22%		0
0%		2
11.11%		0
0%		2
11.11%		1
5.55%		0
0%		17
94.44%
How satisfied are you now with your condition of concentration?G112
66.66%		0
0%		3
16.66%		0
0%		1
5.55%		1
5.55%		1
5.55%		2
11.11%		1
5.55%		15
83.33%
G213
72.22%		0
0%		2
11.11%		0
0%		1
5.55%		0
0%		1
5.55%		1
5.55%		1
5.55%		17
94.44%
How satisfied are you now with the applied therapy?G10
0%		0
0%		0
0%		0
0%		0
0%		0
0%		0
0%		1
5.55%		0
0%		17
94.44%
G20
0%		0
0%		0
0%		0
0%		0
0%		0
0%		0
0%		0
0%		0
0%		18
100%
How was the nocturnal comfort with your occlusal splint? -----------
G23
16.66%		0
0%		3
16.66%		0
0%		3
16.66%		1
5.55%		4
22.22%		2
11.11%		5
27.77%		15
83.33%
How satisfied are you now with the health of your orofacial system?G16
33.33%		0
0%		6
33.33%		0
0%		4
22.22%		0
0%		3
16.66%		2
11.11%		1
5.55%		16
88.88%
G26
33.33%		0
0%		6
33.33%		0
0%		3
16.66%		0
0%		3
16.66%		1
5.55%		0
0%		17
94.44%
How satisfied are you now with yourself?G16
33.33%		0
0%		5
27.77%		0
0%		3
16.66%		1
5.55%		3
16.66%		3
16.66%		1
5.55%		14
77.77%
G26
33.33%		0
0%		4
22.22%		0
0%		4
22.22%		0
0%		3
16.66%		2
11.11%		1
5.55%		16
88.88%
How do you evaluate now your overall quality of life?G13
16.66%		0
0%		5
27.77%		0
0%		4
22.22%		0
0%		3
16.66%		2
11.11%		3
16.66%		16
88.88%
G24
22.22%		0
0%		3
16.66%		0
0%		4
22.22%		0
0%		4
22.22%		1
5.55%		3
16.66%		17
94.44%
Table 6. Statistical results regarding the degree of changes in patients’ life quality after the applied treatments (at baseline and last follow-up session).
Table 6. Statistical results regarding the degree of changes in patients’ life quality after the applied treatments (at baseline and last follow-up session).
BaselineLast Follow-Up Sessionp-Value
p
(Chi sqr)
NeverRarelySometimeUsualAlwaysNeverRarelySometimeUsualAlways
PatientsSleep disruption3115116302310=5.00
Nocturnal bruxism016920313110<2.00
Dry mouth/sore throat0471213314100<2.00
Masseter pain034920322200<2.00
Fatigue, headaches, jaw pain0581211294300=1.00
Difficulty in focusing01121211267300<2.00
Excessive sleepiness 189711284400=2.00
Patient bed partnersSleep disruption012429266400<2.00
Nocturnal bruxism1361214276300=3.00
Snoring0213129303210=1.00
Waking, gasping, choking 045198285300=5.00
Mood changes39897303300=3.00
Difficulty in focusing1351612277200=3.00
Excessive sleepiness 66789294300=1.00
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rezk Gavrilă, T.G.; Bechir, A.; Nicolau, A.C.; Bechir, E.S. Patients’ Satisfaction after the Treatment of Moderate Sleep Apnea and Nocturnal Bruxism with Botox or/and Thermoformed Occlusal Splints: A Pilot Study. J. Pers. Med. 2024, 14, 1029. https://doi.org/10.3390/jpm14101029

AMA Style

Rezk Gavrilă TG, Bechir A, Nicolau AC, Bechir ES. Patients’ Satisfaction after the Treatment of Moderate Sleep Apnea and Nocturnal Bruxism with Botox or/and Thermoformed Occlusal Splints: A Pilot Study. Journal of Personalized Medicine. 2024; 14(10):1029. https://doi.org/10.3390/jpm14101029

Chicago/Turabian Style

Rezk Gavrilă, Taalat Gabriel, Anamaria Bechir, Andrada Camelia Nicolau, and Edwin Sever Bechir. 2024. "Patients’ Satisfaction after the Treatment of Moderate Sleep Apnea and Nocturnal Bruxism with Botox or/and Thermoformed Occlusal Splints: A Pilot Study" Journal of Personalized Medicine 14, no. 10: 1029. https://doi.org/10.3390/jpm14101029

APA Style

Rezk Gavrilă, T. G., Bechir, A., Nicolau, A. C., & Bechir, E. S. (2024). Patients’ Satisfaction after the Treatment of Moderate Sleep Apnea and Nocturnal Bruxism with Botox or/and Thermoformed Occlusal Splints: A Pilot Study. Journal of Personalized Medicine, 14(10), 1029. https://doi.org/10.3390/jpm14101029

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop